We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
No fiscal-year history available for this company yet.
No P/E, the company is not profitable on a trailing basis.
Fujian Haixi Pharmaceuticals Co., Ltd. engages in research and development, production, and sale of pharmaceutical products in China. The company offers drugs for oncology, ophthalmology, respiratory, digestion, cardiovascular, endocrine, and nervous systems, and inflammation. It also provides pharmaceuticals technical services. In addition, the company offers generic alternatives, such as Anbili, a generic of mosapride citrate tablets; Haihuitong 5mg/10mg and 5mg/20mg, a generic of amlodipine besilate and atorvastatin calcium tablets; Ruiantuo, a generic of cinacalcet hydrochloride tablets; and Saixifu, a generic of hydroxychloroquine sulfate tablets. Further, it provides Haibiping, a generic of valsartan and amlodipine tablets; Anyoufan, a generic of escitalopram oxalate tablets; Haikexi, a generic of valsartan tablets; Anfeiping, a generic of diclofenac sodium enteric-coated tablets; and Jishuning, a generic of cetirizine hydrochloride oral solution. Additionally, the company's pipeline includes C019199, a drug candidate targeting the modulation of the immunosuppressive tumor microenvironment for the treatment of advanced osteosarcoma, which has completed phase II clinical trials; HXP056, an oral small-molecule drug designed to treat retinopathy-related diseases, which has completed phase I clinical trial; HXP089, an oral small-molecule drug targeting glioblastoma multiforme; and HXP090, an oral small-molecule drug designed specifically targeting idiopathic pulmonary fibrosis. It sells its products through retail pharmacies, online pharmacies, and internet medical platforms. Fujian Haixi Pharmaceuticals Co., Ltd. was incorporated in 2012 and is based in Fuzhou, China.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save 2637.HK and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
